XTL BIOPHARMACEUTICALS LTD (XTLB) — Institutional Holders, Q2 2026
3 institutional investment managers reported a XTLB position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $20.7K. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
XTLB in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- RHUMBLINE ADVISERSAdded · +241 sh+$658.00
- UBS Group AGNew · +125 sh+$341.00
Biggest sellers
- Noked Israel LtdSold out · -49,722 sh-$135.7K
- SmartHarvest PortfoliosSold out · -13,351 sh-$36.4K
- GAMMA InvestingTrimmed · -2,175 sh-$5.9K
- Tower Research Capital (TRC)Sold out · -244 sh-$666.00
- MORGAN STANLEYSold out · -10 sh-$27.00
XTLB 13F holders ranked 1–3 of 3
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | RHUMBLINE ADVISERS#1 · 6,228 sh | 6,228 | $17.0K | 0.00% | +4.0% |
| 2 | GAMMA Investing#2 · 1,213 sh | 1,213 | $3.3K | — | -64.2% |
| 3 | UBS Group AG#3 · 125 sh | 125 | $341.00 | 0.00% | New |
Funds that sold out of XTLB in Q2 2026 (4)
Held XTLB at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| Noked Israel Ltd49,722 sh | 49,722 | $120.0K |
| SmartHarvest Portfolios13,351 sh | 13,351 | $32.2K |
| Tower Research Capital (TRC)244 sh | 244 | $588.00 |
| MORGAN STANLEY10 sh | 10 | $24.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.